cyclic heptapeptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-05-11. Anything still debated is marked as such rather than presented as settled.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved in the US, EU and Australia | Sale and import restricted; no licensed product |
| Typical test matrices | Urine, serum, seized powder | Urinary detection window is short |
| Primary identification method | LC-MS/MS against a reference standard | High-resolution mass used for confirmation |
| Data sources in the literature | Small trials, case reports, pharmacovigilance | No registrational trial dataset exists |
| Common marketing names | Melanotan 2, MT-II, MT-2 | Label content may not match declared peptide |
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
The enzyme-linked immunosorbent assay (ELISA) (, ) is a commonly used analytical biochemistry assay, first described by Eva Engvall and Peter Perlmann in 1971. The assay is a solid-phase type of enzyme immunoassay (EIA) to detect the presence of a ligand (commonly a protein) in a liquid sample using antibodies directed against the ligand to be measured. ELISA has been used as a diagnostic tool in medicine, plant pathology, and biotechnology, as well as a quality control check in various industries. In the most simple form of an ELISA, antigens from the sample to be tested are attached to a surface. Then, a matching antibody is applied over the surface so it can bind the antigen. This antibody is linked to an enzyme, and then any unbound antibodies are removed. In the final step, a substance containing the enzyme's substrate is added. If there was binding, the subsequent reaction produces a detectable signal, most commonly a color change. Performing an ELISA involves at least one antibody with specificity for a particular antigen. The sample with an unknown amount of antigen is immobilized on solid support (usually a polystyrene microtiter plate) either non-specifically (via adsorption to the surface) or specifically (via capture by another antibody specific to the same antigen, in a "sandwich" ELISA). After the antigen is immobilized, the detection antibody is added, forming a complex with the antigen. The detection antibody can be covalently linked to an enzyme or can itself be detected by a secondary antibody that is linked to an enzyme through bioconjugation.
== Randomised controlled trial (RCT) == The AIDA diabetes simulator has been tested out in a pilot randomised controlled trial (RCT). The protocol used for the RCT was described a priori in the medical / diabetes literature. The study sought to assess whether diabetes educational teaching sessions using the AIDA simulator led to better outcomes than similar diabetes educational teaching sessions without a computer. The study was run at the Ospedale di Marino, near Rome, in Italy by an independent diabetologist / endocrinologist – unconnected with the simulator's development. Twenty-four volunteers (12 male and 12 female) with type 1 diabetes of more than 6-years duration, aged 19–48 years, who gave written informed consent, were randomly assigned to one of two study groups, each receiving different teaching interventions. Group A was exposed to the AIDA diabetes simulator, while Group B (the control group) received conventional lessons with slides and transparencies. Six lessons were held for each group (one per week). At the beginning and end of the study all subjects had their glycated hemoglobin (HbA1c) measured. The subjects also carefully documented the incidence of any symptomatic hypoglycaemic episodes ('hypos'), whether mild (sweating, dizziness), moderate (nausea, vomiting), or severe (requiring assistance). The results seem encouraging. HbA1c levels in Group A dropped significantly from 7.2% to 6.4% after lessons with the diabetes simulator (p = 0.01).
It has been described as a plenum or a field, a conceptualization that opposed Democritus' atomistic ontology. It is maintained that the Aristotelian concept should not be understood as a "stuff" since there is, for example, hyle that is intellectual as well as sensible hyle found in the body. For Aristotle, hyle is composed of four elements – fire, water, air, and earth – but these were not considered pure substances since matter and form exist in a combination of hot, moist, dry, and cold so that everything is united to form the elements. Aristotle defines matter as "that out of which" something is made. For example, letters are the matter of syllables. Thus, "matter" is a relative term: an object counts as matter relative to something else. For example, clay is matter relative to a brick because a brick is made of clay, whereas bricks are matter relative to a brick house. Change is analyzed as a material transformation: matter is what undergoes a change of form. For example, consider a lump of bronze that's shaped into a statue. Bronze is the matter, and this matter loses one form (morphe) (that of a lump) and gains a new form (that of a statue). According to Aristotle's theory of perception, we perceive an object by receiving its form (eidos) with our sense organs. Thus, forms include complex qualia such as colors, textures, and flavors, not just shapes.
Sources: en.wikipedia.org
stomach antrum distension vagal stimulation (mediated by the neurocrine bombesin, or GRP in humans) the presence of partially digested proteins, especially amino acids, in the stomach. Aromatic amino acids are particularly powerful stimuli for gastrin release. hypercalcemia (via calcium-sensing receptors) Gastrin release is inhibited by:
LSD is a chiral compound with two stereocenters at the carbon atoms C-5 and C-8, so that theoretically four different optical isomers of LSD could exist. LSD, also called d-LSD or (+)-LSD, has the absolute configuration (5R,8R). The other stereoisomers are iso-LSD (d-iso-LSD), l-LSD, and l-iso-LSD. The 5S- or levo- stereoisomers of lysergamides do not exist in nature and are not formed during the synthesis from d-lysergic acid. Retrosynthetically, the C-5 stereocenter could be analysed as having the same configuration as the alpha carbon of the naturally occurring amino acid L-tryptophan, the precursor to all biosynthetic ergoline compounds. However, LSD and iso-LSD, the two C-8 isomers, rapidly interconvert in the presence of bases, as the alpha proton is acidic and can be deprotonated and reprotonated. Non-psychoactive iso-LSD, which has formed during the synthesis, can be separated by chromatography and can be isomerized to LSD. Pure salts of LSD are triboluminescent, emitting small flashes of white light when shaken in the dark. LSD is strongly fluorescent and will glow bluish-white under UV light.
Generation of Neutralizing Human Monoclonal Antibodies Against a Therapeutic Target from the Alloy Therapeutics Mouse Generation Using a Molecular Modeling Platform to Guide Therapeutic Antibody Discovery Optimization of Therapeutic Discovery Strategies for Human Antibody Transgenic Animal Platforms Development of Antibody and PK, and ADA Assays for a Cystine Knot Fusion Protein A Rapid, High-Throughput Recombinant Antibody Expression System for Therapeutic Antibody Discovery and Validation Generation of Agonist and Antagonist Human Monoclonal Antibodies Against an Immune Checkpoint Target from the H2L2 Mouse Generation and Selection of Human Monoclonal Antibodies from the OmniRat Therapeutic Antibody Discovery at Antibody Solutions using the OmniAb Platform Development of human antibodies to human vascular endothelial growth factor -C (VEGF-C) and -D (VEGF-D) Obtaining Antibodies to Difficult Membrane Targets through DNA and Cell Immunization Next-Generation Therapeutic Antibody Discovery from Single B-cells Generation and Selection of Human Monoclonal Antibodies from the H2L2 Mouse Generation of Antibodies to Difficult Membrane Protein Targets Development of Antibodies and ELISAs to measure Free and Total Obiltoxaximab (ETI-204) in the Presence of Anthrax Protective Antigen PA63 Discovery of Therapeutic Antibodies to Difficult Membrane Proteins
Tool use by animals may indicate different levels of learning and cognition. The sea otter uses rocks as essential and regular parts of its foraging behavior (smashing abalone from rocks or breaking open shells), with some populations spending 21% of their time making tools. Other tool use, such as chimpanzees using twigs to "fish" for termites, may be developed by watching others use tools and may even be a true example of animal teaching. Tools may even be used in solving puzzles in which the animal appears to experience a "Eureka moment". Other mammals that do not use tools, such as dogs, can also experience a Eureka moment. Brain size was previously considered a major indicator of the intelligence of an animal. Since most of the brain is used for maintaining bodily functions, greater ratios of brain to body mass may increase the amount of brain mass available for more complex cognitive tasks. Allometric analysis indicates that mammalian brain size scales at approximately the 2⁄3 or 3⁄4 exponent of the body mass. Comparison of a particular animal's brain size with the expected brain size based on such allometric analysis provides an encephalization quotient that can be used as another indication of animal intelligence. Sperm whales have the largest brain mass of any animal on earth, averaging 8,000 cubic centimetres (490 cu in) and 7.8 kilograms (17 lb) in mature males. Self-awareness appears to be a sign of abstract thinking. Self-awareness, although not well-defined, is believed to be a precursor to more advanced processes such as metacognitive reasoning.
Sources: en.wikipedia.org
Regulatory treatment varies by country. In the United States, the European Union and Australia it is an unapproved drug and its sale is restricted, while some other jurisdictions list it as prescription-only or controlled. The applicable rules depend on the country of import.
Reversed-phase LC-MS/MS is the usual approach for both identification and quantitation. High-resolution mass spectrometry and peptide mapping serve as confirmatory methods. Immunoassays are rarely used alone because of cross-reactivity.
Published testing of seized and purchased samples frequently reports discrepancies between declared and measured peptide content. Counter-ion content and residual solvents add further variation. Independent analysis is the only way to confirm composition.
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.